The two scientists won the European Inventor Award jointly in the SMEs category from the European Patent Office (EPO) for their vaccine assembly platform, the office announced on Tuesday.
The vaccine could be used to treat different types of cancer, boosting the immune system’s response to the disease and offering new hope for cancer treatment, the EPO saidExternal link.
“Derouazi and Belnoue’s invention assembles three essential components of a vaccine into a single protein [……] to produce vaccines for different types of cancer. They are intended for use alongside treatments such as surgery, chemotherapy and radiotherapy,” the EPO said.
The KISIMA platform was first used to produce a vaccine designed to treat metastatic colorectal cancer, and early-stage human trials are underway.
Derouazi studied biology and biotechnology in Geneva, Berlin and Lausanne before completing a post-doc at the French National Center for Scientific Research in Paris.
Launched in 2006, the award, which is attributed in five different categories, honours individuals and team solutions to some of the biggest challenges, the EPO said.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
The parents of the young jihadist who left for Syria to join the Islamic State have been given suspended sentences by the Federal Criminal Court.
This content was published on
Felix Lehner, Pamela Rosenkranz and Miroslav Sik have been awarded the Swiss Grand Award for Art/Prix Meret Oppenheim 2025.
Nearly 2% of new Swiss disability insurance claims involve Long Covid
This content was published on
Just under 2% of new claims submitted to the disability insurance between 2021 and 2023 concern people suffering from Long Covid.
This content was published on
The watch industry had to contend with a weakening of its exports last year, which reached a volume of CHF25.9 billion ($28.5 billion).
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.